JACQUELINE BUSS: Open Payments
NPI 1750941803 · QUAKERTOWN, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$430 in 20 payments from 13 companies in 2025. Trend: 2023 $602 · 2024 $784 · 2025 $430
Food & beverage: $430
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 3 | $67 |
| AstraZeneca Pharmaceuticals LP | 3 | $49 |
| Lilly USA, LLC | 2 | $48 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $44 |
| Merck Sharp & Dohme LLC | 2 | $40 |
| Astellas Pharma US Inc | 1 | $32 |
| GlaxoSmithKline, LLC. | 1 | $29 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $27 |
| SANOFI-AVENTIS U.S. LLC | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
Products named: JARDIANCE, AIRSUPRA, UBRELVY, XIFAXAN, Veozah, TRELEGY ELLIPTA, TZIELD, VRAYLAR.
Industry payments across PA — which companies pay providers there.
